Subscribe to Newsletter
Manufacture Advanced Medicine

The Cell + Gene Curator

The Cell + Gene Curator collates the week’s discoveries, process innovation, and business updates – delivered straight to your inbox. Subscribe: 

Here, we roundup a selection of some of the most significant research studies – from preclinical studies to clinical trials – from the past year.


Cardiff University team use CRISPR-Cas9 screening to reveal TCR able to recognize and kill most human cancer types via MR1 (in mice and in vitro) [LINK] 


Mice with diabetes "functionally cured" by transplanting islet-sized pancreatic beta cells generated from human pluripotent stem cells [LINK]

CRISPR is used directly in the body (the eye, in this case) for the first time in patient with inherited form of blindness, called Leber congenital amaurosis [LINK]


Researchers use stem cell transplantation in combination with chemotherapy to cure the second-ever patient of HIV [LINK]

The UPenn researchers genetically engineer macrophages to kill solid tumors in both mouse models and human samples – coining the term CAR M-cell therapy [LINK]


“TriCAR” CD19/CD20/CD22 CAR T cell therapy is significantly more effective than T cells targeting CD19 alone in vitro and in animal model [LINK] 

Researchers reprogram skin cells into light-sensing rod photoreceptors used for vision and transplant them into blind mice – restoring their vision [LINK]


Allogene reports overall response rate of 78 percent in trial of off-the-shelf CAR T (ALLO-501) combined with ALLO-647 antibody in patients with non-Hodgkin lymphoma, who had failed to respond to previous therapies [LINK]

Chinese biotech Gracell announces 24-hour “FasT CAR-T” at AACR – and says early clinical results show 20-40 times greater potency in B-ALL compared with conventionally manufactured CAR Ts [LINK]

Researchers injected mice with the FST gene (using an AAV9 vector) to increase the production of follistatin, which helps grow muscle by inhibiting myostatin, resulting in a doubling of muscle mass and strength doubled over four months [LINK]


J&J's anti-BCMA CAR-T for multiple myeloma achieves 25/29 complete responses [LINK]

Sloan Kettering Institute team uses "uPAR-specitic CAR T cells" to "efficiently ablate senescent cells in vitro and in vivo” and reverse some surrogates of aging in mice, such as liver fibrosis [LINK]

Verve Therapeutics researchers knocked out two cholesterol-associated genes, PCSK9 and ANGPTL3, in cynomolgus monkeys, which resulted in up to a 60 and 65 percent reduction in LDL cholesterol and triglycerides respectively [LINK]


Researchers from Baylor College of Medicine use off-the-shelf T cells to eradicate solid tumors in mice; the cells avoid immune rejection with an engineered 4-1BB-specific receptor (4-1BB is a cell surface receptor temporarily upregulated by activated lymphocytes) [LINK]

Auxolytic finds that when UMPS – which normally makes the nutrient uridine – is knocked out in human T cells, the cells become inactive within a week; researchers could then knock out the UMPS gene during cell therapy and give patients an uridine supplement, which they could stop taking if side effects emerge [LINK]


Two brothers at Macquarie University, Australia, use gene therapy to reverse the effects of memory loss associated with Alzheimer's disease in mouse models of advanced dementia [LINK]

Researchers use CRISPR to create brown-fat-like cells from progenitor white fat cells; they transplanted their "HUMBLE" progenitor cells into mice on a high fat diet and found that the mice put on less weight, had greater sensitivity to insulin and greater ability to clear glucose from the blood than the control group [LINK]

A team from the University of Pennsylvania design HIV-specific Dual (4-1BB and CD28) CAR T cells that provide a strong, long-lasting response against HIV-infection in mice while being resistant to the virus itself [LINK]


MSC-derived-extracellular vesicles delivered via the nose alleviate behavioral phenotypes of PCP-treated mice (a model for schizophrenia) [LINK]

AAV2 vectors bind too tightly to HSPG and get trapped before reaching their destination; and a naturally occurring AAV, with a different mechanism, is more successful at delivery into the liver [LINK]

Researchers from the San Diego State University, USA, have created a "CardioCluster" of three types of cells that reduce scar tissue and improve heart fiction in mice; they persist inside heart walls for as long as five months after transplantation [LINK]


University of Wisconsin Madison researchers repair Parkinson's disease-damaged neural circuits and restore motor function in mice using human stem cell-derived neurons [LINK]

University of North Carolina researchers locally deliver GD2-specific CAR T lymphocytes to mice eyes using in situ grafting, and successfully, in combination with IL-15 and an injectable hydrogel, eliminate retinoblastoma tumor cells without impairing mouse vision [LINK]

In study of 43 subjects with B-cell acute lymphoblastic leukemia receiving allogeneic anti-CD19 CAR-T after relapsing post allotransplant, 34 achieve complete histological remission; two die from multiorgan failure and cytokine release syndrome [LINK]


Local tissue inflammation following allogeneic hematopoietic stem cell transplantation is caused by host-derived tissue-resident memory T cells [LINK] 

University College London's GD2-directed CAR T therapy is well tolerated without on-target toxicity in 12 pediatric patients with neuroblastoma – inducing rapid – but ultimately transient – reduction in tumor size in three patients [LINK]

Researchers from Trinity College Dublin develop a gene therapy for dominant optic atrophy (DOA), which protected mice models of the disease and improved mitochondrial performance in human cells that contained mutations in the OPA1 gene [LINK]

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.


From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine